Who
Nadav Kidron
President and CEO
Company insider
Files Form 4 as: President and CEO, Oramed Pharmaceuticals; Director, Nano Dimension; Director, Lifeward.
In numbers
- Trades disclosed
- 96
- Buys
- 7
- Sells
- 3
- Bought
- $276K
- Sold
- $8.8M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 2 Aug 2007
- Last trade
- 24 Sep 2026
- Last filed
- 25 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Sep 2026filed 25 Sep 2026 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —349,497 | filing |
| 24 Sep 2026filed 25 Sep 2026 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —368,765 | filing |
| 24 Sep 2026filed 25 Sep 2026 | ORMP Oramed Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —196,500 | filing |
| 24 Sep 2026filed 25 Sep 2026 | ORMP Oramed Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —196,500 | filing |
| 24 Sep 2026filed 25 Sep 2026 | ORMP Oramed Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —190,000 | filing |
| 24 Sep 2026filed 25 Sep 2026 | ORMP Oramed Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —49,000 | filing |
| 24 Sep 2026filed 25 Sep 2026 | ORMP Oramed Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —97,000 | filing |
| 24 Sep 2026filed 25 Sep 2026 | ORMP Oramed Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —150,000 | filing |
| 24 Sep 2026filed 25 Sep 2026 | ORMP Oramed Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —107,000 | filing |
| 24 Sep 2026filed 25 Sep 2026 | ORMP Oramed Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —190,000 | filing |
| 24 Sep 2026filed 25 Sep 2026 | ORMP Oramed Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —49,000 | filing |
| 24 Sep 2026filed 25 Sep 2026 | ORMP Oramed Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —97,000 | filing |
| 24 Sep 2026filed 25 Sep 2026 | ORMP Oramed Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —150,000 | filing |
| 24 Sep 2026filed 25 Sep 2026 | ORMP Oramed Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —107,000 | filing |
| 24 Sep 2026filed 25 Sep 2026 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —349,497 | filing |
| 24 Sep 2026filed 25 Sep 2026 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —368,765 | filing |
| 21 Aug 2026filed 25 Aug 2026 | NNDM Nano DimensionElectronic Components & EMS | SEC FORM 4 Code X | $15K10,000 at $1.50 | filing |
| 21 Aug 2026filed 25 Aug 2026 | NNDM Nano Dimensionoption or derivative · Electronic Components & EMS | SEC FORM 4 Code X | —100 at $0.00 | filing |
| 21 Aug 2026filed 25 Aug 2026 | NNDM Nano Dimensionoption or derivative · Electronic Components & EMS | SEC FORM 4 Code X | —100 at $0.00 | filing |
| 21 Aug 2026filed 25 Aug 2026 | NNDM Nano DimensionElectronic Components & EMS | SEC FORM 4 Code X | $15K10,000 at $1.50 | filing |
News
Contrasting Oramed Pharmaceuticals (NASDAQ:ORMP) & Generate Biomedicines (NASDAQ:GENB)ORMP · tickerreport.com · 11 Oct 2026Contrasting Recursion Pharmaceuticals (NASDAQ:RXRX) and Oramed Pharmaceuticals (NASDAQ:ORMP)ORMP · dailypolitical.com · 11 Oct 2026
0 headlines in the last 90 days name Nadav Kidron; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.